A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation.

Trial Profile

A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs GSK 958108 (Primary)
  • Indications Premature ejaculation
  • Focus Therapeutic Use
  • Acronyms PoM
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Oct 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 19 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top